Table 4.
Pooled analysis: treatment-emergent ocular adverse events (AEs) in ≥1.0% of all treated study eyes in any treatment group26
| Patients, n (%) |
||||
|---|---|---|---|---|
| Besifloxacin (n = 1192) | Vehicle (n = 616) | Moxifloxacin (n = 579) | P valuea | |
| Total no. of AEs | 191 | 146 | 81 | |
| Patients with ≥1 AE | 139 (11.7) | 101 (16.4) | 54 (9.3) | 0.0055 |
| Vision blurred | 25 (2.1) | 24 (3.9) | 3 (0.5) | 0.0318 |
| Eye irritation | 17 (1.4) | 18 (2.9) | 8 (1.4) | 0.0457 |
| Eye pain | 22 (1.8) | 11 (1.8) | 7 (1.2) | >0.9999 |
| Conjunctivitis | 14 (1.2) | 15 (2.4) | 5 (0.9) | 0.0492 |
| Eye pruritus | 13 (1.1) | 10 (1.6) | 2 (0.3) | 0.3777 |
| Conjunctivitis, bacterial | 7 (0.6) | 9 (1.5) | 2 (0.3) | 0.0678 |
a
P values were based on Fisher’s exact test comparing besifloxacin with vehicle.